Dr. Alex Milstein, VP of Clinical at Cytori presents on the Acute Injury Technology Panel at the Cardiovascular Research Foundation's Conference on Cell Therapy for Cardiovascular Disease on January 25, 2012

1. Cytori Therapeutics
7th International Conference on Cell Therapy for Cardiovascular Disease
Focus on Acute Injury Technologies
25 January 2012
Alex Milstein, M.D.
VP, Clinical Development

2. Real-Time Access to Autologous Regenerative Cells
Cardiovascular
Disease
< 2 hours
Cytori Celution® Regenerative cells
Soft Tissue Repair
Versatile technology; focus on cardiac & soft tissue repair
CE Mark approval in Europe for soft tissue; Seeking CMI in 1H 2012
36+ patents, 100 + filed on device & cells
Celution™ System is not available in the US

3. Acute Myocardial Infarction – The APOLLO Trial
APOLLO TRIAL
• Prospective European Multicenter Trial
• Randomized (3:1)
• Double Blind
• Placebo controlled
• Blinded independent core labs
• Safety & Feasibility Trial
• n = 14 (4 placebo, 10 treated)
• Co-Principal Investigators: Drs. H.J. Duckers
and P.W. Serruys

4. Cell Treated: Better Perfusion of the Heart
6 & 18 month follow-up
Perfusion defect in LAD territory:
Reduction in perfusion defect in patients treated with ADRC compared
to placebo patients as analyzed by MIBI SPECT (TSS scores)
MIBI SPECT TSS change (matched pairs)
10x 9x
improvement improvement
p=NS
Slide: Courtesy
All SPECT images were assessed by an independent, blinded core lab (CCL, Boston, MA) HJ Duckers, MD, PhD

5. Reduction of > 50% in Infarct Size seen with ADRCs
6 & 18 month follow-up
Percent of Left Ventricle Infarcted (%LVI):
Greater improvement in %LVI in ADRC patients vs. to Placebo control patients (late
enhancement cMRI)
change in rel.infarct size (I/LV) (matched pairs)
all pts baseline 6 mo
Placebo 24,7% 24,7%
ADRC 31,6% 15,4%
Means for treatment groups
p=NS Matched-pair analysis
Slide: Courtesy
All MRI images were assessed by an independent, blinded core lab (CCL, Boston, MA) HJ Duckers, MD, PhD

6. Preservation of End-Systolic Volume with ADRCs
6 & 18 month follow-up
Change in ESV
ESV was markedly reduced in ADRC patients as compared to placebo control patients
change in ESV (cc, 2D TTE)
24,4 cc
improvement
(-72,2%)
Slide: Courtesy
All TTE images were assessed by an independent, blinded core lab (CCL, Boston, MA) HJ Duckers, MD, PhD

7. APOLLO: Arrhythmias
Percent of Pa ents with Signific nt
a More ventricular arrhythmias observed in
Ventricular Arrhythmias Control patients
60%  More Significant Ventricular Arrhythmias in
50%
50% control patients
 Higher frequency of recordings with
40%
30% Ventricular Premature Bits (VPB) in Controls
Higher number of VPBs per recording
30%

20% in Controls
10%
0%
Placebo Group 1
Premature Ventricular Contrac ons - Mean Count per Pa ent Premature Ventricular Contrac ons - Mean Cumula ve Count
700 3000
600
2500
500
2000
400
control 1500 control
300 ADRC ADRC
1000
200
500
100
0 0
0.5 1 2 3 4 8 12 16 25 52 77 0.5 1 2 3 4 8 12 16 25 52 77

8. APOLLO: Summary
 ADRCs are safe in the treatment of STEMI
 No safety concerns
 Cell administration is safe
 No new MACE/SAEs
 No Deaths
 Feasibility
 Concordant improvement in infarct and ischemia:
 Mean reduction in Infarct Size is maintained to 18 months
 Improvement in cardiac perfusion is maintained to 18 months
 May have positive impact on arrhythmia in cell-treatment patents

9. Cytori Cardiac Program: Present and Future
Celution™ System is CE Marked in the EU
Acute Myocardial Infarction:
• European APOLLO Trial – completing 36-mo FU
• Pivotal European ADVANCE Trial – ramping up
• US trial in AMI – to follow ADVANCE
Chronic Myocardial Ischemia:
• European PRECISE Trial – completing 36-mo FU
• US ATHENA Trial – IDE filed

10. AMI - THE ADVANCE TRIAL
• Primary endpoint: cMRI infarct size at 6 months
• Randomized, Double-blind, Placebo-controlled
• N ≤ 360, at up to 35 sites in the EU
• 23 sites selected & committed
• Various states of regulatory process by country
• Co-PIs Drs. H.J. Duckers and G. Pompilio
• Independent blinded core labs will evaluate all imaging data
• Independent DMC provides safety oversight
• Independent CEC will adjudicate all germane events
• Currently enrolling & treating patients
18-mo data from Apollo support trial design for ADVANCE

11. Thank you